fda restrictions bpc-157 compounding is reviewing seven peptides this week, BPC-157, MOTS-c, and Epitalon among them. Committee meets Thursday and Friday, and the likely outcome is tighter on pharmacies. Read past the headline 83% of peptide-aware Americans want

83% of peptide aware Americans want the FDA to make peptides more accessible AOL The experts will take votes on whether the FDA should allow seven popular peptides to be added to a list of substances that are safe for compounding by pharmacies. FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring!

SKU: 62073665273 · From iglepidom.org